mProX™ Human PTGER3 Stable Cell Line

Product Information

Target Protein

PTGER3

Target Family

Prostanoid Family

Target Protein Species

Human

Host Cell Type

HIO180; OVCAR-3; CHO-K1; HEK293

Target Classification

GPCR Cell Lines

Target Research Area

Cancer Research; CNS Research; Inflammation Research; Reproductive Research

Related Diseases

Mast Cell Neoplasm; Antenatal Bartter Syndrome

Gene ID

5733

UniProt ID

P43115

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

The human gene PTGER3 encodes PTGER3, a prostaglandin receptor for prostaglandin E2 (PGE2). The PTGER3 receptor performs a number of tasks. First, the capacity of aspirin and other nonsteroidal anti-inflammatory medicines to lower fever brought on by inflammation in animals and possibly humans is due to suppression of the PGE2-EP3 pathway. Then, in models of allergic conjunctivitis and contact hypersensitivity, EP3 receptor-deficient mice and/or wild type mice treated with an EP3 receptor agonist are similarly shielded from allergic reactions. Therefore, at least in mice, EP3 appears to have a significant role in lowering allergy sensitivity. Third, research on tissues from mice, guinea pigs, humans, and guinea pigs shows that PGE2 activates EP3 to cause coughing responses. The customized PTGER3 stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat Natalie

The PTGER3 cell lines definitely stand out. They are an excellent investment because of their unparalleled performance and quality. Dec 05 2022

chat Verified Customer

chat Andrew

We are so lucky to work with creative biolabs. May 31 2023

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 PTGER3 overexpression in human tumors is associated.

Real-time PCR and Western blot analyses for PTGER3 were performed on a panel of OC and normal ovarian cell lines as stated in the Methods section. The loading control used was beta-actin.

Ref: Rodriguez-Aguayo, Cristian, et al. "PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis." EBioMedicine 40 (2019): 290-304.

Pubmed: 30655206

DOI: 10.1016/j.ebiom.2018.11.045

Research Highlights

For tumor-related angiogenesis, tumor development, and chemoresistance, prostaglandin E2-prostaglandin E2 receptor EP3 (PTGER3) signaling is essential. However, it is unknown what causes these effects in ovarian cancer.
Rodriguez-Aguayo, Cristian, et al. "PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis." EBioMedicine 40 (2019): 290-304.
Pubmed: 30655206 DOI: 10.1016/j.ebiom.2018.11.045

This study not only revealed a portion of the molecular mechanism of CKI in GC therapy, but it also offered a cutting-edge systems pharmacology approach to investigate the mechanisms of formulations of traditional Chinese medicine.
Zhou, Wei, et al. "An advanced systems pharmacology strategy reveals AKR1B1, MMP2, PTGER3 as key genes in the competing endogenous RNA network of compound kushen injection treating gastric carcinoma by integrated bioinformatics and experimental verification." Frontiers in Cell and Developmental Biology 9 (2021): 742421.
Pubmed: 34646828 DOI: 10.3389/fcell.2021.742421